Items tagged with Drug-resistant TB
RESIST-TB April 2024 newsletter (post)
RESIST-TB released its April 2024 newsletter with the latest updates and research publications on drug-resistant TB.
RESIST-TB webinar: VQUIN and TB-CHAMP results (post)
RESIST-TB will host a webinar on 11 April 2024 to present results from the two randomized, controlled trials -- VQUIN and TB-CHAMP -- that used levofloxacin for preventive therapy in adult and pediatric household contacts of people with multidrug- and rifampicin-resistant TB (MDR/RR-TB).
WHO announces forthcoming updates on co-administration of treatment for drug-resistant TB and hepatitis C (post)
9 April 2024 — In a Rapid Communication issued today, the World Health Organization (WHO) is announcing updates on co-administration of treatment for drug-resistant tuberculosis and hepatitis C (HCV). The evidence suggests that concomitant treatment for HCV and multidrug-resistant or rifampicin-resistant TB (MDR/RR-TB) is feasible, with potential benefits outweighing the harms. Co-administration may increase MDR/RR-TB treatment success and reduce failures, losses to follow-up, and deaths. Adherence support for HCV treatment during MDR/RR-TB treatment is also acknowledged.
WHO BPaLM Accelerator Platform (post)
The WHO BPaLM Accelerator Platform was established in January 2023, right after the update of the World Health Organization (WHO) guidelines on the treatment of drug-resistant TB in 2022. The purpose of the WHO BPaLM Accelerator Platform is to support countries and stakeholders in information exchange and technical discussions to address challenges in the adoption and implementation of the BPaLM/BPaL regimen (consisting of bedaquiline, pretomanid, linezolid and moxifloxacin, with the provision of dropping moxifloxacin in case of confirmed resistance to fluoroquinolones). This is also to support the Call to Action on rolling out of the BPaLM regimen and other short regimens for treatment of drug-resistant TB that was initiated by WHO and its multiple partners.
High prevalence of pre-XDR-TB in patients who didn't respond to treatment: Study (post)
Study of 600 TB patients in Mumbai found 51% with pre-XDR-TB and 15.5% with MDR-TB. Whole genome sequencing crucial for accurate treatment decisions.
Johnson & Johnson receives positive CHMP opinion recommending full approval for SIRTURO® (bedaquiline) for treatment of multidrug-resistant TB (post)
-- CHMP recommends Conditional Marketing Authorisation be converted into standard Marketing Authorisation
-- Recommendation supported by results from the Phase 3 STREAM Stage 2 study, which show bedaquiline-containing regimens offer significant improvement compared to other available therapies
The harsh reality of multidrug-resistant TB in children (post)
Only about 12-16% of children and young adolescents with MDR-TB or rifampicin-resistant TB were diagnosed and treated in 2022. Diagnosing them is hard, and the treatment course is lengthy and side-effect-prone.
Post-TB lung disease: A patient's story (post)
Global TB infections are rising, with some patients suffering lung damage long after they are cured. There are also new strains of drug-resistant TB.
RESIST-TB May 2024 newsletter (post)
RESIST-TB released its May 2024 newsletter with the latest updates and research publications on drug-resistant TB.
WHO updates list of drug-resistant bacteria most threatening to human health (post)
The World Health Organization (WHO) released its updated Bacterial Priority Pathogens List (BPPL) 2024, featuring 15 families of antibiotic-resistant bacteria grouped into critical, high and medium categories for prioritization. The list provides guidance on the development of new and necessary treatments to stop the spread of antimicrobial resistance (AMR).
Page 85 of 117 · Total posts: 0
←First 84 85 86 Last→